Translational data on Regeneron’s leptin receptor agonist support further development

Nov. 24, 2023

REGN-4461 (mibavademab) is a monoclonal antibody targeting leptin receptor (LEP-R) under development by Regeneron Pharmaceuticals Inc. It acts as an allosteric agonist and does not compete with leptin binding to LEP-R.

Today's news in brief

BioWorld

BioWorld briefs for May 7, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 5, 2026

Rendering of a key measles protein targeted by neutralizing human antibodies

First measles treatment advances as vaccination rates drop

BioWorld

Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...

The epidermal growth factor receptor in the inactive (left) and active (right) form.

Cytospire raises £61M series A to target EGFR in solid tumors

BioWorld

Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...

Bio Korea 2026: US policy risks shift to execution framework

BioWorld

Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...